The Emily Whitehead Foundation is moving toward direct patient and caregiver support while also engaging with structural payment and regulatory challenges
George Eastwood has spent much of his career close to the science and manufacturing that make advanced therapies possible. Coming from the cell and gene therapy “tool space,” he worked in areas such as cell collection, research products and the manufacturing ecosystems that support clinical development. For years, the prevailing belief was straightforward: if the science worked and the manufacturing could scale, patients would naturally follow.
But as CAR-T and gene-edited therapies began moving from trials into real-world use, another picture emerged.
“When you glance deeper and deeper into the patient’s need and what happens once something is commercially approved, we can see so many systemic and practical challenges in delivering cures to patients,” George said. “We are living in a healthcare system not built for delivering cures, both from a complicated logistics perspective, from a payment perspective and at the highest level in awareness and understanding perspective.”
Speaking to Xtalks in his role as Executive Director of the Emily Whitehead Foundation, George highlighted that those challenges are no longer theoretical. They show up in scheduling, reimbursement, referral pathways, caregiver burden and in the sheer complexity of moving a living therapy from collection to manufacturing to reinfusion.
“The great thing is there’s so much innovation happening,” he added. “The hard part is delivering that innovation at scale, at the speed at which it’s coming.”
From Grant-Making to Hands-On Patient and Caregiver Support
The Foundation, born from Emily Whitehead’s own CAR-T journey, has evolved alongside the field. In recent years, it has deliberately shifted its focus.
“Over the past couple of years, we’ve shifted strategy away from being a grant-making organization to being really focused on how we can best support patients who receive any advanced therapy and their caregivers,” George explained.
That support now includes building tailored patient and caregiver programs, helping families navigate complex treatment pathways and addressing what he described as “the structural barriers in payment policy and regulation that are hindering our delivery right now for CAR-T therapies and ex vivo gene-edited cell therapies.”
Looking ahead to AAV-based gene therapies and ultra-rare diseases, he sees many of the same system-level issues repeating. The therapies may differ, but the access challenges often rhyme.
“How can we make changes to the system itself to enable access to more than the 20% of eligible CAR-T patients that are currently receiving it commercially?” he asked.
Following the Journey of the Cells, and the Patient
What makes cell and gene therapy different, George believes, is how visible the patient’s role is in the science itself.
“You’re literally having the raw material taken out of your body and put back in or having a gene directly edited in your body,” he said. “I think that’s given us a big opportunity to connect to science a lot more.”
In manufacturing, he had seen how bottlenecks in chemistry, manufacturing and control (CMC), vector production and cell processing could slow development. At the Foundation, he now sees how those same bottlenecks ripple forward into patient access, hospital readiness and caregiver stress.
The journey of a therapy — from research and manufacturing through to delivery in the clinic — mirrors the journey of the patient. Telling that story in a connected way is something the Foundation is keen to amplify, especially as N-of-1 (meaning a treatment essentially designed for one patient) and rare disease programs become more common.
“How do we use those stories to tell the stories of the technologies that enable the cures that are being created?” he said.
Hearing the Patient Voice Early
For George, one of the most powerful lessons from the advocacy world is how early the patient perspective should enter scientific thinking.
“I think the headline of the answer is it’s never too early to think about the patient,” he said.
He recalled a moment from a rare disease panel that stayed with him. A parent, speaking with a pharmaceutical company about trial endpoints, explained that no dataset could fully capture daily life with his child’s condition.
“‘We can look at endpoints and measure data, but until you come to my house for six hours and spend six hours with my son with this disease, you’ll probably never understand the difference that it can make,’” George said the parent told them. “‘You may be thinking cure, but how about 20 steps so he doesn’t need to be walked to the bathroom every day?’”
For George, that perspective can be transformative, not just for regulators or clinicians, but for scientists and founders themselves.
“Even a scientific founder would love to hear that because it may, A, motivate that scientist to think differently and outside the box, and B, to understand the real-world plight of the patient outside of the really difficult clinical trial design and endpoints that we look at in curative medicine,” he said.
When the Medical Journey Suddenly Changes
One area the Emily Whitehead Foundation is beginning to look at more closely is what happens when long-standing patterns of illness and care suddenly shift.
George pointed to sickle cell disease as an example. For many patients, life has been organized around regular hospital visits, transfusions and the constant risk of vaso-occlusive crises. Those routines, while difficult, become part of daily structure.
“If you speak to sickle cell patients who have had vaso-occlusive crises and transfusions twice a month their whole life, when that goes away, a lot of structure goes away and your identity as a patient goes away,” he said.
The change can be dramatic. Treatments that remove or sharply reduce disease burden do more than alter lab values or clinical outcomes. They can reshape how people understand themselves and how their lives are organized.
“So how do you empower those patients to rebuild that structure when these cures are so dramatic and dynamic that they can change your whole identity?” George asked.
From his perspective, this is not a problem that ends with the administration of a therapy. It extends into recovery, adjustment and long-term support.
Comments
Add a comment